Targeting PI3K/mTOR signaling in cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21987725.
- Also identified by DOI 10.1158/0008-5472.CAN-11-1699.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The American Association for Cancer Research (AACR) Special Conference on Targeting PI3K/mTOR Signaling in Cancer was held in San Francisco, California from February 24 to 27, 2011. The meeting was cochaired by Drs. Lewis C. Cantley, David M. Sabatini, and Funda Meric-Bernstam. The main focus of this event was the therapeutic potential of drugs targeting the PI3K/mTOR signaling pathway for the treatment of cancer. This article summarizes the recent discoveries in the field, with particular emphasis on the major themes of the conference.
Medical subject headings
- Antineoplastic Agents
- Neoplasms
- Phosphatidylinositol 3-Kinases
- Signal Transduction
- TOR Serine-Threonine Kinases